The medicine is being examined as one of three repurposed drugs in the ACTIV-6 research, which is recruiting participants with mild-to-moderate COVID-19. Repurposed drugs are ones that the FDA has previously approved for use in different medical contexts.
Adrian Hernandez, M.D., the study’s administrative main investigator and executive director of the DCRI, stated, “Data from modeling studies, published clinical research, and community interest support investigating multiple doses and durations of ivermectin.” “This expansion will yield important data regarding the function of ivermectin and whether it can assist individuals with mild-to-moderate COVID-19 symptoms in preventing the disease from getting worse.”
For six days, the extended study medication arm is administered at a dose of 600 mcg/kg each day. The FDA has not approved ivermectin, a medication used to treat parasitic infections, to treat COVID-19. It should only be used as a participant in a research trial, like ACTIV-6.
Enrollment in the arm testing ivermectin at 400 mcg/kg daily for three days is been closed due to successful results for use Ivermectin 12 Mg. The ACTIV-6 website lists the treatment arms that are now accepting enrollment, and the ACTIV-6 testing platform will eventually include more arms.
Over 3,000 people have already signed up for ACTIV-6, or “The Randomized Trial to Evaluate Efficacy of Repurposed Medications,” a double-blind, countrywide study. It is anticipated to enroll close to 15,000 people from all over the country.
Participants in the study must be 30 years of age or older, have experienced a positive COVID-19 test within the last 10 days, and have experienced at least two symptoms of the condition for no more than seven days in order to be eligible. Potential volunteers can indicate their interest in the study by contacting 833-385-1880 or by completing the online survey on the study’s website, in order to enroll.
Participants can come from anywhere in the US, and there is no charge for the free shipment of medications to their homes. No visits or treatments to the study clinic are necessary. To take part, you must take the drug and record your symptoms for ninety days by filling out surveys over the phone or online.
The DCRI principal investigator in charge of the study’s clinical coordinating center, Susanna Naggie, M.D., stated, “We have treatments for people with mild-to-moderate COVID-19 who are at high risk for hospitalization or death, but they remain in limited supply and each current authorized drug has limitations.” “We need more medications that can be taken at home to treat the symptoms of the virus to help people feel better faster, especially as cases of the Omicron variant surge nationally, straining health systems and medical personnel.”
Naggie mentioned that more drugs will be added to the trial over time. The drugs selected for ACTIV-6 research have demonstrated promise in treating COVID-19 in the outpatient context, but more testing in a more extensive, meticulous, and randomised clinical trial is required.